These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28488141)

  • 1. Elevated T cell activation score is associated with improved survival of breast cancer.
    Lu L; Bai Y; Wang Z
    Breast Cancer Res Treat; 2017 Aug; 164(3):689-696. PubMed ID: 28488141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study.
    Liu JN; Kong XS; Huang T; Wang R; Li W; Chen QF
    Front Immunol; 2020; 11():2048. PubMed ID: 33072070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
    Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
    Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.
    Lu L; Huang H; Zhou J; Ma W; Mackay S; Wang Z
    BMC Cancer; 2019 Apr; 19(1):387. PubMed ID: 31023256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.
    Tu L; Guan R; Yang H; Zhou Y; Hong W; Ma L; Zhao G; Yu M
    Int J Cancer; 2020 Jul; 147(2):423-439. PubMed ID: 31721169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prognostic Significance of the Tumor-infiltrating Programmed Cell Death-1
    Shibutani M; Maeda K; Nagahara H; Fukuoka T; Nakao S; Matsutani S; Hirakawa K; Ohira M
    Anticancer Res; 2017 Aug; 37(8):4165-4172. PubMed ID: 28739701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults.
    Boer MC; van Meijgaarden KE; Goletti D; Vanini V; Prins C; Ottenhoff TH; Joosten SA
    Tuberculosis (Edinb); 2016 Mar; 97():163-71. PubMed ID: 26750180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database.
    Deng L; Gyorffy B; Na F; Chen B; Lan J; Xue J; Zhou L; Lu Y
    J Thorac Oncol; 2015 Jul; 10(7):1020-6. PubMed ID: 26134222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma.
    Lu L; Gaffney SG; Cannataro VL; Townsend J
    Oral Oncol; 2020 Feb; 101():104554. PubMed ID: 31887619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subgrouping breast cancer patients based on immune evasion mechanisms unravels a high involvement of transforming growth factor-beta and decoy receptor 3.
    Bou-Dargham MJ; Liu Y; Sang QA; Zhang J
    PLoS One; 2018; 13(12):e0207799. PubMed ID: 30513096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
    Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
    PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating CD8
    Song Q; Ren J; Zhou X; Wang X; Song G; Hobeika A; Yuan Y; Lyerly HK
    Cytotherapy; 2018 Jan; 20(1):126-133. PubMed ID: 28988693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.